Tg Therapeutics (TGTX) Revenue (2017 - 2026)
Tg Therapeutics (TGTX) posted quarterly Revenue of $204.9 million for Q1 2026, up 69.56% year-over-year from $120.9 million in Q1 2025, and up 6.41% quarter-over-quarter from $192.6 million in Q4 2025.
Tg Therapeutics (TGTX) Revenue (2017 - 2026) Analysis & Trends
Tg Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $204.9 million for Q1 2026.
- In Q1 2026, Revenue rose 69.56% year-over-year to $204.9 million; the TTM figure through Mar 2026 stood at $700.3 million (up 81.26% YoY), while the FY2025 annual figure was $616.3 million, up 87.32% from the prior year.
- Revenue for Q1 2026 stood at $204.9 million, up from $192.6 million in the prior quarter.
- The five-year high for Revenue was $204.9 million in Q1 2026, with the low at $80000.0 in Q4 2022.
- The 5-year median for Revenue is $73.5 million (2024), against an average of $81.6 million.
- The sharpest annual moves came in 2022 and 2023: Revenue plunged 96.55% in 2022, then surged 176298.94% in 2023.
- Tg Therapeutics' Revenue stood at $80000.0 in 2022, then jumped by 54863.75% to $44.0 million in 2023, then jumped by 146.04% to $108.2 million in 2024, then soared by 78.0% to $192.6 million in 2025, then climbed by 6.41% to $204.9 million in 2026.
- Business Quant data shows TGTX's Revenue at $204.9 million in Q1 2026, $192.6 million in Q4 2025, and $161.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 240.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.34 Mn |
| Mar 31, 2026 | 204.92 Mn |
| Dec 31, 2025 | 192.57 Mn |
| Sep 30, 2025 | 161.71 Mn |
| Jun 30, 2025 | 141.15 Mn |
| Mar 31, 2025 | 120.86 Mn |
| Dec 31, 2024 | 108.19 Mn |
| Sep 30, 2024 | 83.88 Mn |
| Jun 30, 2024 | 73.47 Mn |
| Mar 31, 2024 | 63.47 Mn |
| Dec 31, 2023 | 43.97 Mn |
| Sep 30, 2023 | 165.82 Mn |
| Jun 30, 2023 | 16.07 Mn |
| Mar 31, 2023 | 7.80 Mn |
| Dec 31, 2022 | 80,000.00 |
| Sep 30, 2022 | 94,000.00 |
| Jun 30, 2022 | 594,000.00 |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 2.32 Mn |
| Sep 30, 2021 | 2.03 Mn |